News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rexahn Pharmaceuticals, Inc. Initiates Dosing in Phase I Trial of SupinoxinTM (RX-5902) a Candidate for Treating Solid Cancer Tumors


8/7/2013 10:05:19 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company announced today the commencement of patient dosing with SupinoxinTM (RX-5902) in a Phase I clinical trial designed to study safety and efficacy in patients with solid cancer tumors.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES